Growth hormone deficiency and clotting

Not Applicable

Completed

• Conditions: Patients with hypothalamo-pituitary pathology, proven to be severely growth hormone deficient; Nutritional, Metabolic, Endocrine; Idiopathic growth hormone deficiency

• Registration Number: ISRCTN59234325
• Lead Sponsor: eeds Teaching Hospitals NHS Trust (UK)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2013-01-29
• Study Completion: 2016-04-01
• Last Update Posted: 11 June 2018

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 140

Inclusion Criteria

1. Able to give written consent
2. Adults over age 18 years, and of either gender with confirmed GHD (insulin stimulation test <3 ug/L)
3. Other hormone replacement therapy stable for at least three months

Exclusion Criteria

1. Active malignancy
2. An acute vascular event within three months of the study
3. Any therapy other than hormone replacement
4. Serum creatinine >120 mol/l
5. Abnormal liver function tests (LFTs) [alanine transaminase (ALT) >3 fold upper limit of normal]

Study & Design

• Study Type: Observational
• Study Design: Not specified